Cardlytics (NASDAQ:CDLX – Get Free Report)‘s stock had its “hold” rating restated by stock analysts at Needham & Company LLC in a report issued on Friday,Benzinga reports.
CDLX has been the subject of a number of other research reports. Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Evercore ISI initiated coverage on Cardlytics in a research note on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $6.92.
Get Our Latest Stock Report on CDLX
Cardlytics Price Performance
Cardlytics (NASDAQ:CDLX – Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The firm had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. During the same period last year, the firm earned ($0.26) EPS. The business’s quarterly revenue was down 15.1% compared to the same quarter last year. As a group, sell-side analysts predict that Cardlytics will post -1.52 earnings per share for the current fiscal year.
Insider Activity
In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the firm’s stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the transaction, the chief executive officer now owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. This trade represents a 11.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alexis Desieno sold 8,854 shares of Cardlytics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $3.67, for a total transaction of $32,494.18. Following the completion of the transaction, the chief financial officer now directly owns 121,976 shares of the company’s stock, valued at $447,651.92. This trade represents a 6.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,007 shares of company stock worth $251,297 in the last quarter. 4.40% of the stock is owned by company insiders.
Hedge Funds Weigh In On Cardlytics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Tallon Kerry Patrick purchased a new stake in Cardlytics in the 4th quarter worth approximately $37,000. Atom Investors LP purchased a new position in shares of Cardlytics in the third quarter valued at $33,000. XTX Topco Ltd purchased a new stake in Cardlytics during the second quarter valued at approximately $107,000. SG Americas Securities LLC bought a new stake in shares of Cardlytics in the 3rd quarter valued at approximately $45,000. Finally, Intech Investment Management LLC purchased a new position in shares of Cardlytics in the 3rd quarter worth approximately $47,000. 68.10% of the stock is currently owned by hedge funds and other institutional investors.
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
See Also
- Five stocks we like better than Cardlytics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Options Trading – Understanding Strike Price
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
- With Risk Tolerance, One Size Does Not Fit All
- Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.